University of California San Francisco

Lucas Wachsmuth, MD, PhD

Lucas Wachsmuth
Lucas Wachsmuth, MD, PhD

Resident (PGY-2)
General Surgery

[email protected]

Education

Institution Degree Dept or School End Date
Duke University MD, PhD Tumor Immunology 05/2025
University of Georgia BS Biochemistry, Biology 05/2014

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. Adapting Laser Interstitial Thermal Therapy for the Treatment of Naturally Occurring Intracranial Tumors in Dogs.
    Mariani CL, Wachsmuth LP, Bramall AN, Meritet DM, Hatfield J, Tsvankin V, Keenihan EK, Tokarz DA, Tyc R, Nolan MW, Fecci PE| | PubMed
  2. Autonomic modulation of the immune response and implications for CNS malignancies.
    Wachsmuth LP, Srinivasan ES, Puviindran BJ, Haskell-Mendoza AP, DeSpenza T, Fecci PE| | PubMed
  3. Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion.
    Waibl Polania J, Hoyt-Miggelbrink A, Tomaszewski WH, Wachsmuth LP, Lorrey SJ, Wilkinson DS, Lerner E, Woroniecka K, Finlay JB, Ayasoufi K, Fecci PE| | PubMed
  4. Combination checkpoint blockade and laser interstitial thermal therapy in radiographically progressive non-small cell lung cancer brain metastases.
    Haskell-Mendoza AP, Srinivasan ES, Gonzalez AT, Reason EH, Jackson JD, Flusche AM, Wachsmuth LP, Lerner E, Underwood D, Buckley ED, Zaidi SE, Herndon JE, Fecci PE| | PubMed
  5. The LITT Fit in neuro-oncology: indications, imaging, and adjunctive therapies.
    Haskell-Mendoza AP, Gonzalez AT, Reason EH, Flusche AM, Chongsathidkiet P, Wachsmuth LP, Goodwin CR, Fecci PE| | PubMed
  6. Gold Nanostars Obviate Limitations to Laser Interstitial Thermal Therapy (LITT) for the Treatment of Intracranial Tumors.
    Srinivasan ES, Liu Y, Odion RA, Chongsathidkiet P, Wachsmuth LP, Haskell-Mendoza AP, Edwards RM, Canning AJ, Willoughby G, Hinton J, Norton SJ, Lascola CD, Maccarini PF, Mariani CL, Vo-Dinh T, Fecci PE| | PubMed
  7. CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis.
    Lerner EC, Woroniecka KI, D'Anniballe VM, Wilkinson DS, Mohan AA, Lorrey SJ, Waibl-Polania J, Wachsmuth LP, Miggelbrink AM, Jackson JD, Cui X, Raj JA, Tomaszewski WH, Cook SL, Sampson JH, Patel AP, Khasraw M, Gunn MD, Fecci PE| | PubMed
  8. Foxn1 overexpression promotes thymic epithelial progenitor cell proliferation and mTEC maintenance, but does not prevent thymic involution.
    Li J, Wachsmuth LP, Xiao S, Condie BG, Manley NR| | PubMed
  9. Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs.
    Fletcher RE, Nunes NS, Patterson MT, Vinod N, Khan SM, Mendu SK, Li X, de Paula Pohl A, Wachsmuth LP, Choo-Wosoba H, Eckhaus MA, Venzon DJ, Kanakry CG| | PubMed
  10. Systemic immune derangements are shared across various CNS pathologies and reflect novel mechanisms of immune privilege.
    Lorrey SJ, Waibl Polania J, Wachsmuth LP, Hoyt-Miggelbrink A, Tritz ZP, Edwards R, Wolf DM, Johnson AJ, Fecci PE, Ayasoufi K| | PubMed